Health

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...
GSK plc announces positive results from DREAMM-8 trial at ASCO 2024, showing significant improvements in PFS for Blenrep combination therapy...
GSK plc celebrates favorable jury verdict in first Zantac trial, highlighting scientific consensus on ranitidine safety and ongoing defense against claims...
AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...
AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...
AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
Haleon plc (NYSE/LON:HLN) impresses with solid Q1 results, showcasing organic revenue growth despite market challenges. Explore key sectors and financial highlights here. #Haleon #ConsumerHealth..
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Haleon plc appoints Dawn Allen as Chief Financial Officer, effective 28 October 2024. Tobias Hestler to step down due to health condition...
GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...
Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...
AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...
GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
Search

Funds

Financial Services

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...
GSK plc announces positive results from DREAMM-8 trial at ASCO 2024, showing significant improvements in PFS for Blenrep combination therapy...
GSK plc celebrates favorable jury verdict in first Zantac trial, highlighting scientific consensus on ranitidine safety and ongoing defense against claims...
AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...
AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...
AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
Haleon plc (NYSE/LON:HLN) impresses with solid Q1 results, showcasing organic revenue growth despite market challenges. Explore key sectors and financial highlights here. #Haleon #ConsumerHealth..
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Haleon plc appoints Dawn Allen as Chief Financial Officer, effective 28 October 2024. Tobias Hestler to step down due to health condition...
GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...
Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...
AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...
GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
Search

Funds

Health

FTSE 100

Funds